Yahoo Finance The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer
For Immediate Release
Chicago, IL – October 11, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bristol Myers Squibb BMY, Mirati Therapeutics MRTX, Eli Lilly LLY, POINT Biopharma PNT and Pfizer PFE.
Here are highlights from Tuesday’s Analyst Blog:
Cancer Biotecha Pique Buyout Interest: Recent Deals in Focus
Mergers and acquisitions (M&A) in pharma and biotech are back in focus after two important deals were announced in a fortnight.
Bristol Myers Squibb announced that it will acquire commercial-stage oncology company Mirati Therapeutics for a total equity value of $4.8 billion-plus contingent value right of approximately $1.0 billion. The acquisition will add Mirati's new lung cancer drug Krazati (adagrasib) to BMY's strong oncology portfolio. The drug was approved by the FDA in December 2022 for the treatment of adult patients with KRAS-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.
Bristol Myers will also get access to Mirati's early-stage candidate MRTX1719, a potential first-in-class MTA-cooperative PRMT5 inhibitor. It is currently in phase I development and has shown encouraging early efficacy data across several tumor types. Mirati had long been a buyout target.
Last week, Eli Lilly offered to buy POINT Biopharma, a maker of next-generation radioligand therapies for treating cancers, for approximately $1.4 billion in cash. Radioligand therapy is a type of precision cancer treatment, which combines a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle).
Point Biopharma's lead pipeline candidate is PNT2002, which is being developed to treat metastatic castration-resistant prostate cancer after progression on hormonal treatment. The phase III SPLASH study on PNT2002 is complete and top-line data is expected in the fourth quarter of 2023. The acquisition of POINT Biopharma, if successfully closed, will bolster Lilly's portfolio of cancer drugs.
There have been quite a few M&A deals in the pharma and biotech sector so far this year.
M&A deals in the pharma and biotech sector have been quite active this year so far.
The first half of 2023 saw some mega-merger announcements. Pfizer offered to buy cancer drugmaker Seagen for $43 billion in March. The acquisition is expected to be closed in late 2023 or early 2024. Merck closed the acquisition of Prometheus Biosciences (announced in April) for approximately $10.8 billion in June. Amgen's $28 billion acquisition of Horizon Therapeutics closed last week after the companies resolved the pending Federal Trade Commission administrative lawsuit.
Generally, the drug and biotech sector is characterized by aggressive M&A activity. Given that it takes several years and millions of dollars to develop new therapeutics from scratch, large pharmaceutical companies, sitting on huge piles of cash, regularly buy innovative small/mid-cap biotech companies to build out their pipelines. Fast-growing and lucrative markets such as oncology, rare disease and cell and gene therapy are mostly the focus areas for M&A activities.
However, the M&A deals of 2023, Bristol-Myers/Mirati, Lilly/ POINT Biopharma and Pfizer/Seagen, show that there is an increasing interest of drugmakers in companies making innovative cancer treatments. In an evolving global oncology landscape, emerging biotechs making cancer drugs with novel mechanisms of action and providing better outcomes than currently available drugs are attracting buyout interest. The market for cancer medicines is expected to continue to increase as disease rates rise in leaps and bounds globally. Consequently, biotechs focused on cancer medicines are likely to see an increase in buyout interest.
Bristol-Myers and Eli Lilly have a Zacks Rank #3 (Hold) each. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Mirati Therapeutics, Inc. (MRTX) : Free Stock Analysis Report
POINT Biopharma Global Inc. (PNT) : Free Stock Analysis Report
